Quinine dihydrochloride injection

Quinine is a quinoline derivative that can bind to the DNA of malarial parasites to form a complex, inhibit DNA replication and RNA transcription, and thus inhibit the protein synthesis of the protozoa. Its effect is weaker than that of chloroquine. In addition, quinine can reduce the oxygen consumption of malarial parasites, inhibit the phosphorylase in malarial parasites and interfere with their sugar metabolism. Quinine also causes malarial pigment aggregation, but the development is slow, rarely forms large clumps, and is often accompanied by cell death. Electron microscopic observation shows that the nucleus and outer membrane of the protozoa are swollen, and there are small vacuoles. The blood cell particles aggregate in the small vacuoles, which is different from the pigment aggregation of chloroquine. In the blood, a certain concentration of quinine can cause premature rupture of parasitized red blood cells, thereby preventing the maturation of schizonts. This product is ineffective in the early stage of malaria, and a long course of treatment can cure malignant malaria, but it has no direct effect on the gametocytes of malignant malaria, so it cannot interrupt transmission.

The main ingredient of this product is quinine dihydrochloride, the chemical name of which is 6-methoxy (8a, 9R) cinchonis 9-ol dihydrochloride

This product is a colorless or slightly yellow clear liquid.

Used to treat cerebral malaria and other severe forms of falciparum malaria.

1. The dosage for adults is 5-10 mg/kg (maximum 500 mg) based on body weight. Add to 500 ml of sodium chloride injection and drip intravenously. The drip should be completed in 4 hours. Repeat once after 12 hours. After the condition improves, switch to oral administration. 2. The dosage for children is the same as that for adults, 5-10 mg/kg (maximum 500 mg) based on body weight.

1. If the daily dosage of this product exceeds 1g or it is used for a long time, it often causes cinchona reaction, which is roughly similar to the reaction of salicylic acid, with symptoms such as tinnitus, headache, nausea, vomiting, vision and hearing loss, etc. In severe cases, temporary deafness occurs, which can usually be recovered after stopping the drug; 2. When the dose is greater than 4g within 24 hours, it can directly damage the nerve tissue and constrict the retinal blood vessels, resulting in narrowing of the visual field, diplopia, amblyopia, etc.; 3. When poisoned by a large dose, in addition to the aggravation of the above reactions, it can also inhibit the myocardium and dilate peripheral blood vessels, causing a sudden drop in blood pressure, slow and shallow breathing, fever, irritability, delirium, etc., and most patients die from respiratory paralysis; 4. A small number of patients are highly sensitive to quinine, and a small amount can cause severe cinchona reaction; 5. A small number of patients with malignant malaria who use a small amount of quinine may suffer from acute hemolysis (black water fever) and die; 6.

It is forbidden for pregnant women to use.

1. Antacids and aluminum-containing preparations can delay or reduce the absorption of quinine; 2. When anticoagulants are used in combination with quinine, the anticoagulant effect can be enhanced; 3. Muscle relaxants such as succinylcholine and tubocurarine can react with quinine and may cause respiratory depression; 4. When quinidine is used in combination with quinine, the cinchona reaction can be increased; 5. Urine alkalinizing agents such as sodium bicarbonate can increase the reabsorption of quinine by the renal tubules, leading to an increase in quinine blood concentration and toxicity; 6. Combination with vitamin K can increase the absorption of quinine; 7. Combination with buclizine, cyclizine, meclizine, phenothiazines, thioxanthenes, trimethofenzamide, and aminoglycoside antibiotics can cause tinnitus and dizziness; 8. When used in combination with nifedipine (nifedipine), the concentration of free quinine increases.

Keep away from light and store in a sealed container.

1ml:0.25g

12 months

KPC Pharmaceuticals, Inc.

• Founded in:

  1995-12-14

• Address:

  No. 166, Keyi Road, High-tech Industrial Development Zone, Kunming, Yunnan Province

• Tax NO.:

  91530000216562280W

• Registered Funds:

  757.986969 yuan

• Website:

  Log in to view

• Email:

  Log in to view